Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Orphan Designations For Pediatric Subgroups Of Common Diseases To End

Executive Summary

US FDA's draft guidance closes loophole where sponsors could obtain an orphan designation for a pediatric subset and then be exempt from requirements to conduct pediatric studies.


Related Content

Are Orphan Incentives Necessary For Development? Sponsors Aren't So Sure
Orphan Incentives: Voucher Price Drop Gives Some Sponsors 'Pause'
US FDA Outlines Streamlined Development Path For Targeted Therapies
ICH Expansion To Bring New Challenges For Global Consensus On Pediatric Extrapolation
Keytruda's New Tissue-Agnostic Indication Could Prompt Orphan Policy Changes
Orphan Pediatric Loophole To Be Closed By US FDA
Pediatric Cancer Study Requirements Added To FDA User Fee Bill
PDUFA VI: Pediatrics Group Seeks Earlier And Faster Studies
Orphan Drug Act: Congressional, FDA, NORD Reviews Come Amid Pricing Debate
Disease 'Subsetting' Not Driving Jump In Orphan Designations, US FDA Says





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts